Search Results - "Dijksterhuis, W. P. M."

Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods by van de Water, L. F., van Kleef, J. J., Dijksterhuis, W. P. M., Henselmans, I., van den Boorn, H. G., Vaarzon Morel, N. M., Schut, K. F., Daams, J. G., Smets, E. M. A., van Laarhoven, H. W. M.

“…Purpose Cancer patients are increasingly involved in decision-making processes. Hence, clinicians need to inform patients about the risks and benefits of…”
Get full text

Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study by Mokadem, I., Dijksterhuis, W. P. M., van Putten, M., Heuthorst, L., de Vos-Geelen, J. M., Haj Mohammad, N., Nieuwenhuijzen, G. A. P., van Laarhoven, H. W. M., Verhoeven, R. H. A.

“…Background In most western European countries perioperative chemotherapy is a part of standard curative treatment for gastric cancer. Nevertheless, recurrence…”
Get full text

Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study by van Kleef, J. J., Dijksterhuis, W. P. M., van den Boorn, H. G., Prins, M., Verhoeven, R. H. A., Gisbertz, S. S., Slingerland, M., Mohammad, N. Haj, Creemers, G.-J., Neelis, K. J., Heisterkamp, J., Rosman, C., Ruurda, J. P., Kouwenhoven, E. A., van de Poll-Franse, L. V., van Oijen, M. G. H., Sprangers, M. A. G., van Laarhoven, H. W. M.

“…Background Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall…”
Get full text

A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy by Faiz, Z., Dijksterhuis, W.P.M., Burgerhof, J.G.M., Muijs, C.T., Mul, V.E.M., Wijnhoven, B.P.L., Smit, J.K., Plukker, J.T.M.

“…Isolated local recurrent or persistent esophageal cancer (EC) after curative intended definitive (dCRT) or neoadjuvant chemoradiotherapy (nCRT) with initially…”
Get full text

811PSecond-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: A population-based study by Dijksterhuis, W P M, Verhoeven, R H A, Slingerland, M, Haj Mohammad, N, de Vos-Geelen, J, Beerepoot, L V, Van Voorthuizen, T, Creemers, G-J, van Oijen, M, van Laarhoven, H W M

“…Abstract Background Metastatic esophagogastric cancer patients can be treated with paclitaxel/ramucirumab, or another taxane, or an irinotecan-containing…”
Get full text

813PIncreased assessment of HER2 in metastatic gastroesophageal cancer patients: A nationwide population-based cohort study by Dijksterhuis, W P M, Verhoeven, R H A, Meijer, S L, Slingerland, M, Haj Mohammad, N, de Vos-Geelen, J, Beerepoot, L V, Van Voorthuizen, T, Creemers, G-J, van Oijen, M, van Laarhoven, H W M

“…Abstract Background Addition of trastuzumab to first-line palliative chemotherapy in esophagogastric cancer patients with HER2 overexpression has shown to…”
Get full text